

Munich Cancer Registry



- ▶ Incidence and Mortality
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

ICD-10 C00-C14: HN cancer

Survival

Year of diagnosis	1988-1997	1998-2019
Patients	2,525	11,106
Diseases	2,581	11,528
Cases evaluated	2,285	8,680
Creation date	01/27/2021	
Database export	01/07/2021	
Population	4.92 m	



Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninstr. 15
Munich, 81377
Germany

<https://www.tumorregister-muenchen.de/en>

<https://www.tumorregister-muenchen.de/en/facts/surv/sC0014E-ICD-10-C00-C14-HN-cancer-survival.pdf>

Index of figures and tables

Fig./Tbl.	Page
1a Relative survival by period of diagnosis (chart)	3
1b Survival by period of diagnosis (table)	3
2a Survival by sex (chart)	4
2b Survival by sex (table)	4
3a Observed survival by age category (chart)	5
3b Relative survival by age category (chart)	5
3c Survival by age category (table)	6
4a Relative survival by ICD-10 classification (chart)	7
4b Survival by ICD-10 classification (table)	7
4c Conditional survival by extent of disease (chart)	9
4d Conditional survival by extent of disease (table)	9
5a Time to first progression (chart)	10
5b Time to first progression (table)	10
5c Observed post-progression survival (chart)	12
5d Observed post-progression survival (table)	12
5e Observed post-progression survival by period of progression (chart)	13
5f Observed post-progression survival by period of progression (table)	13




Figure 1a. Relative survival of patients with HN cancer by period of diagnosis. Included in the evaluation are 10,879 cases diagnosed between 1988 and 2019.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2017, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Period of diagnosis					
	1988-1997 n=2,278		1998-2006 n=3,358		2007+ n=5,243	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	77.4	78.8	77.2	78.5	80.0	81.5
2	59.8	61.9	62.3	64.4	67.4	69.9
3	51.5	54.2	53.7	56.4	60.2	63.5
4	45.9	49.2	48.9	52.2	55.2	59.3
5	41.8	45.6	45.3	49.2	51.8	56.7
6	38.1	42.2	42.2	46.6	48.4	54.0
7	35.1	39.5	39.4	44.3	45.0	51.2
8	31.8	36.5	36.9	42.2	42.5	49.3
9	29.9	34.9	34.3	40.0	40.1	47.5
10	27.3	32.5	32.4	38.6	37.9	45.7
11	25.4	30.7	30.3	36.8	35.0	43.2
12	23.7	29.1	28.5	35.2	33.6	41.9
13	21.5	27.0	26.6	33.6		
14	20.3	26.0	24.6	31.9		
15	18.3	23.9	22.8	30.2		
Median	3.2		3.8		5.5	

Table 1b. Observed (obs.) and relative (rel.) survival of patients with HN cancer by period of diagnosis for period 1988-2019 (N=10,879).




Figure 2a. Survival of patients with HN cancer by sex. Included in the evaluation are 8,601 cases diagnosed between 1998 and 2019.

Years	Sex			
	Male n=6,234		Female n=2,367	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	77.3	78.6	83.2	84.9
2	62.5	64.7	72.9	75.6
3	54.4	57.3	66.0	69.7
4	49.4	52.9	61.2	65.8
5	45.9	50.1	57.7	63.0
6	42.7	47.5	54.1	60.2
7	39.6	44.9	51.1	57.8
8	36.9	42.6	48.8	56.1
9	34.6	40.7	45.6	53.4
10	32.6	39.1	43.4	51.9
11	30.4	37.3	40.5	49.2
12	28.3	35.5	38.8	48.2
13	26.2	33.6	36.8	46.7
14	24.3	31.9	34.1	44.1
15	22.6	30.4	30.9	41.0
Median	3.9		7.4	

Table 2b. Observed (obs.) and relative (rel.) survival of patients with HN cancer by sex for period 1998-2019 (N=8,601).




Figure 3a. Observed survival of patients with HN cancer by age category. Included in the evaluation are 8,601 cases diagnosed between 1998 and 2019.




Figure 3b. Relative survival of patients with HN cancer by age category. Included in the evaluation are 8,601 cases diagnosed between 1998 and 2019.

Years	Age category							
	0-49 yrs n=1,357		50-59 yrs n=2,684		60-69 yrs n=2,639		70+ yrs n=1,921	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	87.6	87.7	82.0	82.5	77.5	78.6	70.4	74.3
2	76.7	77.0	66.2	67.0	64.8	66.6	57.1	63.4
3	70.1	70.5	58.3	59.4	56.9	59.5	48.7	57.2
4	66.0	66.7	53.3	54.7	51.6	54.7	43.8	54.4
5	63.7	64.5	49.9	51.7	48.4	52.3	38.5	50.8
6	61.6	62.5	46.3	48.4	45.6	50.2	34.2	48.1
7	59.5	60.6	43.4	45.8	42.8	48.1	29.6	44.5
8	57.4	58.7	41.5	44.2	39.9	45.8	26.1	42.1
9	55.5	57.0	39.1	42.2	37.2	43.7	22.7	39.5
10	54.0	55.7	36.9	40.3	34.5	41.6	21.3	40.0
11	51.7	53.5	34.9	38.5	31.6	39.2	18.8	38.9
12	49.6	51.7	33.2	37.2	29.1	37.1	17.0	38.7
13	48.0	50.2	31.1	35.3	26.5	35.0	15.2	38.7
14	45.7	48.2	28.6	33.1	24.6	33.5	13.4	37.8
15	44.8	47.4	26.4	31.1	22.2	31.5	10.9	35.4
Median	11.9		5.0		4.4		2.9	

Table 3c. Observed (obs.) and relative (rel.) survival of patients with HN cancer by age category for period 1998-2019 (N=8,601).




Figure 4a. Relative survival of patients with HN cancer by ICD-10 classification. Included in the evaluation are 8,601 cases diagnosed between 1998 and 2019.

Years	ICD-10 classification													
	C00 Lip n=269		C01 Base of tongue n=656		C02 Tongue n=979		C03 Gums n=302		C04 Floor of mouth n=813		C05 Palate n=355		C06 Mouth unspec. n=224	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	96.6	100.8	77.0	78.3	84.5	86.0	77.0	79.2	81.3	82.4	84.7	85.7	74.3	76.8
2	88.2	96.7	62.2	64.2	68.8	71.2	66.8	70.4	68.2	69.9	72.7	74.7	63.6	67.0
3	82.6	94.5	55.5	58.3	62.8	66.1	60.0	64.6	59.8	62.1	64.8	67.3	57.4	61.8
4	79.3	94.6	52.5	56.1	58.8	62.9	54.4	60.0	52.9	55.4	61.3	64.7	52.9	58.5
5	74.4	92.6	48.1	52.3	55.1	60.0	50.9	57.5	49.7	52.7	58.0	61.8	49.8	56.5
6	67.4	87.9	45.2	50.0	51.8	57.4	47.0	54.4	46.3	49.8	55.8	60.4	47.5	55.3
7	64.9	87.4	41.3	46.6	49.0	55.2	44.2	52.7	42.2	46.1	52.0	57.4	43.2	51.5
8	62.2	87.3	38.0	43.8	45.1	51.7	41.6	50.9	38.3	42.4	48.9	54.5	39.2	48.0
9	56.9	82.9	36.4	42.7	42.5	49.5	38.2	48.3	36.7	41.2	42.0	47.9	36.1	45.9
10	54.2	81.9	34.4	41.2	40.0	47.6	37.6	48.8	33.3	38.1	39.1	45.4	35.3	45.3
Median	10.9		4.5		6.7		5.3		4.8		7.5		4.9	

cont'd Years	ICD-10 classification													
	C07 Parotid gland n=472		C08 Salivary glands unspec. n=147		C09 Tonsil n=1,337		C10 Oropharynx n=394		C11 Nasopharynx n=259		C12 Piriform sinus n=433		C13 Hypopharynx n=794	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	90.1	92.8	85.8	87.7	81.4	82.7	69.2	70.0	81.4	82.1	77.4	78.4	60.2	61.1
2	83.1	87.7	74.0	77.1	70.3	72.4	53.2	54.7	74.0	75.5	60.0	61.7	42.4	43.7
3	75.0	81.3	67.1	70.6	62.9	65.8	44.9	46.7	66.2	68.3	49.2	51.4	34.5	36.0
4	69.4	77.1	59.1	63.6	58.6	62.0	40.2	42.4	62.3	65.0	42.5	45.1	29.2	31.0
5	66.6	75.6	53.9	58.8	55.7	60.0	38.3	40.7	58.7	61.7	36.3	39.3	26.6	28.6
6	63.5	73.8	52.1	57.8	52.6	57.5	34.8	37.5	56.4	60.1	32.6	35.8	24.2	26.4
7	61.4	72.7	48.7	55.5	49.1	54.7	30.6	33.7	53.9	58.5	30.9	34.4	23.0	25.5
8	57.7	69.9	48.7	55.3	47.0	53.1	29.0	31.9	51.8	57.1	28.0	31.8	21.6	24.3
9	55.3	68.1	47.3	54.3	45.1	52.0	27.6	30.9	51.8	57.3	26.4	30.6	20.4	23.0
10	53.5	67.2	45.8	53.7	43.6	51.1	26.5	29.8	49.9	56.5	25.5	29.9	18.8	21.9
Median	11.6		6.4		6.7		2.3		9.5		2.8		1.5	

ICD-10 classification		
C14		
<i>cont'd</i>	Lip,mouth,pha r. unspec. n=1,167	
Years	obs. %	rel. %
0	100.0	100.0
1	77.2	78.3
2	60.9	62.6
3	51.4	53.7
4	46.0	48.7
5	42.0	45.2
6	38.1	41.7
7	34.5	38.4
8	33.3	37.6
9	29.0	33.5
10	26.2	30.7
Median	3.2	

Table 4b. Observed (obs.) and relative (rel.) survival of patients with HN cancer by ICD-10 classification for period 1998-2019 (N=8,601).




Figure 4c. Conditional relative 2-year survival of patients with HN cancer by extent of disease. For 7,940 of 8,601 cases diagnosed between 1998 and 2019 valid data could be obtained for this item. For a total of 7,914 cases an evaluable classification was established. The grey line represents the subgroup of 687 patients with missing values regarding extent of disease (8.0 % of 8,601 patients, the percent values of all other categories are related to n=7,914).

Years	Extent of disease							
	Local		Regional		Distant		NA/NOS	
	n	Cond. surv. % 2 yrs	n	Cond. surv. % 2 yrs	n	Cond. surv. % 2 yrs	n	Cond. surv. % 2 yrs
0	3,066	84.1	4,469	62.3	379	26.7	687	52.1
1	2,677	85.2	3,349	68.8	150	47.7	385	77.2
2	2,320	89.4	2,535	78.8	91	62.1	316	83.8
3	2,063	91.9	2,045	85.8	64	77.0	273	87.5
4	1,835	92.2	1,700	89.1	47	86.9	235	90.3
5	1,641	91.7	1,443	89.2	38	94.2	209	92.8
6	1,414	92.2	1,227	90.9	34	93.2	188	90.7
7	1,206	92.1	1,029	92.2			167	91.2
8	1,027	92.3	869	93.6			142	94.0
9	851	91.9	713	93.7			120	92.6
10	709	93.4	588	90.8			97	95.8

Table 4d. Conditional relative 2-year survival of patients with HN cancer by extent of disease for period 1998-2019 (N=7,914).

Conditional relative survival rates refer to the relative survival probability, in this case for 2 years after cancer diagnosis, compared to the age- and sex-matched population (=100 %) under the condition of being alive for a certain time period (x-axis in Figure 4a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 91.9% (n=2,063).




Figure 5a. Time to first progression of 8,560 patients with HN cancer diagnosed between 1998 and 2019 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

	Type of progression							Distant metastasis (CI)
	Any type (CI)	Any type (1-KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)		
N	8,202	8,202	8,560	8,560	8,560	8,560	8,205	
Events	4,017	4,017	1,295	1,295	577	577	1,647	
compet.	1,407		4,156		4,725		3,330	
Years	%	%	%	%	%	%	%	
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
1	28.5	29.2	6.0	6.9	3.3	3.8	8.5	
2	39.1	40.4	10.4	12.9	5.1	6.3	14.6	
3	43.5	45.2	12.1	15.4	6.0	7.6	17.3	
4	45.8	47.8	13.3	17.3	6.3	8.3	18.5	
5	47.1	49.4	13.9	18.4	6.5	8.6	19.3	
6	48.3	50.9	14.5	19.6	6.6	8.9	19.8	
7	49.2	51.9	15.0	20.5	6.9	9.4	20.3	
8	50.1	53.2	15.5	21.6	6.9	9.5	20.7	
9	50.9	54.3	16.0	22.7	7.1	9.8	21.0	
10	51.5	55.2	16.4	23.5	7.2	10.2	21.2	
11	52.2	56.3	16.7	24.3	7.3	10.4	21.5	
12	52.6	56.8	17.0	25.0	7.3	10.5	21.8	
13	52.8	57.2	17.1	25.2	7.3	10.6	22.0	
14	53.2	57.9	17.1	25.5	7.4	10.7	22.1	
15	53.5	58.5	17.3	26.0	7.4	10.7	22.4	

<i>cont'd</i>	Type of progression		
	Distant metast. (1- KM)	NOS (CI)	NOS (1-KM)
N	8,205	8,557	8,557
Events	1,647	1,798	1,798
compet.		3,567	
Years	%	%	%
0	0.0	0.0	0.0
1	9.4	15.0	15.7
2	16.8	18.1	19.6
3	20.5	19.3	21.2
4	22.2	20.0	22.2
5	23.5	20.4	23.0
6	24.3	20.8	23.6
7	25.0	21.1	24.1
8	25.7	21.4	24.8
9	26.4	21.6	25.1
10	26.8	21.8	25.5
11	27.5	22.0	26.1
12	28.0	22.2	26.4
13	28.4	22.3	26.7
14	28.9	22.4	27.2
15	29.5	22.6	27.6

Table 5b. Time to first progression of patients with HN cancer for period 1998-2019 (N=8,560), also showing the total of progression events (Events) and of deaths as competing risk (compet.).




Figure 5c. Observed post-progression survival of 3,022 patients with HN cancer diagnosed between 1998 and 2019. These 3,022 patients with documented progression events during their course of disease represent 35.3 % of the totally 8,560 evaluated cases (incl. M1, n=358, 4.2 %). Patients with cancer relapse documented via death certificates only were excluded (n=1,366, 16.0 %). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potentially considered in more than one subgroup.

Years	Type of progression				
	Any type n=3,022 %	Local relapse n=1,298 %	Lymph node n=576 %	Distant metastasis n=1,324 %	NOS n=854 %
0	100.0	100.0	100.0	100.0	100.0
1	50.1	50.4	51.5	35.2	56.7
2	34.5	34.5	36.9	20.5	41.2
3	27.6	28.3	28.7	14.2	35.4
4	23.6	25.5	23.2	11.5	30.5
5	21.4	23.9	20.7	10.4	26.8
6	19.4	21.0	18.5	9.0	24.6
7	17.6	19.3	16.9	8.4	21.3
8	16.2	16.5	14.9	8.1	20.4
9	15.0	15.2	14.9	7.5	18.5
10	13.6	14.0	13.8	6.7	16.6

Table 5d. Observed post-progression survival of patients with HN cancer for period 1998-2019 (N=3,022).




Figure 5e. Observed post-progression (distant metastasis) survival of 1,600 patients with HN cancer diagnosed between 1988 and 2019 by period of progression.

Years	Period of progression		
	1988-1997 n=185 %	1998-2006 n=500 %	2007+ n=915 %
0	100.0	100.0	100.0
1	29.6	30.9	38.1
2	18.3	17.1	22.3
3	13.7	11.2	16.0
4		9.3	12.8
5		8.9	11.4
6		8.5	9.4
7		8.1	8.5
8		7.0	8.0
9		6.4	
10		6.1	

Table 5f. Observed post-progression (distant metastasis) survival of patients with HN cancer for period 1988-2019 by period of progression (N=1,600).

Shortcuts

MCR	Munich Cancer Registry, Germany	
NCI	National Cancer Institute, USA	
SEER	Surveillance, Epidemiology, and End Results, USA	
UICC	Union for International Cancer Control, Geneva	
DCO	Death certificate only	Death certificate provides the only notification to the registry.
NA	Not available	
NOS	Not otherwise specified	
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause
RS	Relative survival	Survival compared to “general population”, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival
AS	Assembled survival	Assembled chart of observed, expected, relative survival
CS	Conditional survival	Survival probability under the condition of surviving a given period of time
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression
1-KM		1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)
CI		Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C00-C14: HN cancer [Internet]. 2021 [updated 2021 Jan 27; cited 2021 Mar 1]. Available from: <https://www.tumorregister-muenchen.de/en/facts/surv/sC0014E-ICD-10-C00-C14-HN-cancer-survival.pdf>

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.